Shares of United Therapeutics Corp. (NASDAQ:UTHR) dropped 2.4% on Thursday . The company traded as low as $111.93 and last traded at $112.09, with a volume of 327,114 shares trading hands. The stock had previously closed at $114.83.

UTHR has been the topic of a number of research analyst reports. Wedbush reiterated an “outperform” rating and set a $229.00 target price (down from $238.00) on shares of United Therapeutics Corp. in a research report on Thursday, March 24th. Leerink Swann reiterated a “market perform” rating on shares of United Therapeutics Corp. in a research report on Saturday, April 16th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $122.00 target price (down from $150.00) on shares of United Therapeutics Corp. in a research report on Monday, April 11th. HC Wainwright downgraded United Therapeutics Corp. from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $175.00 to $95.00 in a research report on Wednesday, June 15th. Finally, Zacks Investment Research upgraded United Therapeutics Corp. from a “hold” rating to a “strong-buy” rating and set a $125.00 target price on the stock in a research report on Tuesday, July 5th. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $138.00.

The stock’s 50 day moving average is $109.06 and its 200 day moving average is $118.08. The stock has a market cap of $5.02 billion and a PE ratio of 6.43.

United Therapeutics Corp. (NASDAQ:UTHR) last announced its quarterly earnings data on Thursday, April 28th. The biotechnology company reported $3.02 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.21 by $0.19. The company earned $369 million during the quarter, compared to analyst estimates of $395.02 million. The company’s quarterly revenue was up 12.7% compared to the same quarter last year. During the same period last year, the company posted $2.55 EPS. On average, equities analysts expect that United Therapeutics Corp. will post $14.17 EPS for the current fiscal year.

In other news, CEO Martine A. Rothblatt sold 5,546 shares of the firm’s stock in a transaction dated Thursday, May 5th. The stock was sold at an average price of $107.79, for a total value of $597,803.34. Following the sale, the chief executive officer now directly owns 5,786 shares of the company’s stock, valued at $623,672.94. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 1,261 shares of the firm’s stock in a transaction dated Thursday, June 2nd. The shares were sold at an average price of $120.79, for a total value of $152,316.19. Following the completion of the sale, the chief executive officer now directly owns 1,501 shares in the company, valued at $181,305.79. The disclosure for this sale can be found here.

Several large investors have modified their holdings of the stock. State of Tennessee Treasury Department increased its stake in shares of United Therapeutics Corp. by 29.9% in the fourth quarter. State of Tennessee Treasury Department now owns 86,900 shares of the biotechnology company’s stock valued at $13,609,000 after buying an additional 20,000 shares in the last quarter. TrimTabs Asset Management LLC increased its stake in shares of United Therapeutics Corp. by 1.9% in the fourth quarter. TrimTabs Asset Management LLC now owns 13,856 shares of the biotechnology company’s stock valued at $2,170,000 after buying an additional 258 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of United Therapeutics Corp. by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 138,293 shares of the biotechnology company’s stock valued at $21,660,000 after buying an additional 4,251 shares in the last quarter. Matarin Capital Management LLC acquired a new stake in shares of United Therapeutics Corp. during the fourth quarter valued at about $4,154,000. Finally, Globeflex Capital L P acquired a new stake in shares of United Therapeutics Corp. during the fourth quarter valued at about $2,061,000.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.